Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics,
and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult
subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway
mutations.